SCHEMBL2188550

SCHEMBL2188550

COC(=O)c1ccc(Oc2ccc(OS(=O)(=O)C(F)(F)F)cc2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STS P08842 1/20 0.59
RAB9A P51151 3/20 0.56
CA1 P00915 2/20 0.51
CA2 P00918 2/20 0.51
LMNA P02545 2/20 0.50
CXCR2 P25025 2/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
ALDH1A1 P00352 1/20 0.48
MAPT P10636 4/20 0.47
TSHR P16473 1/20 0.46
TDP1 Q9NUW8 1/20 0.44
CA12 O43570 1/20 0.44
CA7 P43166 1/20 0.44
CA9 Q16790 1/20 0.44
CA14 Q9ULX7 1/20 0.44
MMP2 P08253 1/20 0.44
MMP9 P14780 1/20 0.44
CXCR1 P25024 1/20 0.44
FAAH O00519 1/20 0.43
EPHX2 P34913 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1928327 0.95 STS (0.65) STSRAB9ACA1CA2LMNA
SCHEMBL6132404 0.91 STS (0.59) STSRAB9ACA1CA2LMNA
SCHEMBL6352149 0.90 STS (0.48) STSRAB9ACA1CA2LMNA
Methylparaben SCHEMBL5481174 0.89 CA1 (0.61) STSRAB9ACA1CA2LMNA
SCHEMBL3004003 0.83 STS (0.51) STSRAB9ACA1CA2LMNA
SCHEMBL3316267 0.82 STS (0.49) STSRAB9ACA1CA2LMNA
SCHEMBL10206864 0.81 TSHR (0.44) STSRAB9ASMN1; SMN2ALDH1A1MAPT
SCHEMBL5179823 0.81 PTPN1 (0.53) RAB9ACA1CA2LMNACXCR2
SCHEMBL69218 0.81 CA1 (0.75) STSRAB9ACA1CA2SMN1; SMN2
SCHEMBL15912453 0.80 PLAU (0.52) STSRAB9ACA1CA2CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8748621-B2 1,3-disubstituted 4-(aryl-X-phenyl)-1H-pyridin-2-ones Janssen Pharmaceuticals, Inc. (US) 2014-06-10 US disclosed
US-8748621-B2 1,3-disubstituted 4-(aryl-X-phenyl)-1H-pyridin-2-ones Janssen Pharmaceuticals, Inc. (US) 2014-06-10 US disclosed
US-8748621-B2 1,3-disubstituted 4-(aryl-X-phenyl)-1H-pyridin-2-ones Janssen Pharmaceuticals, Inc. (US) 2014-06-10 US disclosed
US-20120309793-A1 1,3-DISUBSTITUTED 4-(ARYL-X-PHENYL)-1H-PYRIDIN-2-ONES ADDEX PHARMA, S.A. (CH) 2012-12-06 US disclosed
US-20120309793-A1 1,3-DISUBSTITUTED 4-(ARYL-X-PHENYL)-1H-PYRIDIN-2-ONES ADDEX PHARMA, S.A. (CH) 2012-12-06 US disclosed
US-20120309793-A1 1,3-DISUBSTITUTED 4-(ARYL-X-PHENYL)-1H-PYRIDIN-2-ONES ADDEX PHARMA, S.A. (CH) 2012-12-06 US disclosed
US-8252937-B2 1,3-disubstituted 4-(aryl-X-phenyl)-1H-pyridin-2-ones Janssen Pharmaceuticals, Inc. (US) 2012-08-28 US disclosed
US-8252937-B2 1,3-disubstituted 4-(aryl-X-phenyl)-1H-pyridin-2-ones Janssen Pharmaceuticals, Inc. (US) 2012-08-28 US disclosed
US-8252937-B2 1,3-disubstituted 4-(aryl-X-phenyl)-1H-pyridin-2-ones Janssen Pharmaceuticals, Inc. (US) 2012-08-28 US disclosed
EP-2200985-B1 1,3-DISUBSTITUTED 4-(ARYL-X-PHENYL)-1H-PYRIDIN-2-ONES ORTHO MCNEIL JANSSEN PHARM (US) 2011-07-13 EP disclosed
EP-2200985-B1 1,3-DISUBSTITUTED 4-(ARYL-X-PHENYL)-1H-PYRIDIN-2-ONES ORTHO MCNEIL JANSSEN PHARM (US) 2011-07-13 EP disclosed
US-20100286206-A1 1,3-DISUBSTITUTED 4-(ARYL-X-PHENYL)-1H-PYRIDIN-2-ONES ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) 2010-11-11 US disclosed
US-20100286206-A1 1,3-DISUBSTITUTED 4-(ARYL-X-PHENYL)-1H-PYRIDIN-2-ONES ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) 2010-11-11 US disclosed
US-20100286206-A1 1,3-DISUBSTITUTED 4-(ARYL-X-PHENYL)-1H-PYRIDIN-2-ONES ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) 2010-11-11 US disclosed
WO-2009033702-A1 1,3-DISUBSTITUTED 4-(ARYL-X-PHENYL)-1H-PYRIDIN-2-ONES ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) 2009-03-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120309793-A1 1,3-DISUBSTITUTED 4-(ARYL-X-PHENYL)-1H-PYRIDIN-2-ONES GRM2, GRM1, GRM3 STS 2736/4885RAB9A 2277/4885CA1 4254/4885
US-20100286206-A1 1,3-DISUBSTITUTED 4-(ARYL-X-PHENYL)-1H-PYRIDIN-2-ONES GRM2, GRM1, GRM3 STS 2736/4885RAB9A 2277/4885CA1 4254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.